Moon­Lake's mid-stage IL-17 da­ta sent shares sky­rock­et­ing. Now it plans to sell $250M in stock

Moon­Lake Im­munother­a­peu­tics is seek­ing to raise $250 mil­lion from in­vestors in a pub­lic of­fer­ing, the biotech said af­ter Mon­day’s clos­ing bell. The move comes af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER